<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026438</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-livertransplant</org_study_id>
    <nct_id>NCT04026438</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT)</brief_title>
  <official_title>Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we aim to analyse the effect of phosphate supplementation on donors undergoing&#xD;
      partial hepatectomy for LDLT. In Group A, we are going to supplement phosphate in donors&#xD;
      postoperatively from day 1 to day 5. We will analyse the trend of serum phosphate levels in&#xD;
      donors postoperatively, its correlation with occurrence of postoperative complications and&#xD;
      status of liver regeneration by CT volumetry on Day 7. Group B will constitute the controls&#xD;
      for the study and hence attempt to find out the effect of phosphate supplementation in all&#xD;
      donors postoperatively. We will analyse the data and elucidate the value of phosphate&#xD;
      supplementation in reducing the occurrence of complications and effect on liver regeneration&#xD;
      in donors in LDLT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Actual">February 24, 2021</completion_date>
  <primary_completion_date type="Actual">February 24, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative complications</measure>
    <time_frame>1 month</time_frame>
    <description>Outcome of phosphate supplementation in reducing the occurrence of postoperative complications assessed by Clavien Dindo grading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trend of serum phosphorous levels</measure>
    <time_frame>1 week</time_frame>
    <description>Serum phosphorous levels will be done daily and its trend will be compared in both the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends in post-operative liver function tests</measure>
    <time_frame>1 week</time_frame>
    <description>Liver function tests will be done in both groups and its correlation with serum phosphate levels will be correlated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital, ICU stay</measure>
    <time_frame>Till patient is discharged on an average of 10 days</time_frame>
    <description>ICU stay and total hospital stay in the group will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Complication, Postoperative</condition>
  <condition>Regeneration Liver</condition>
  <arm_group>
    <arm_group_label>Intervention Arm - potassium phosphate injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Phosphate Injection</intervention_name>
    <description>One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline</description>
    <arm_group_label>Intervention Arm - potassium phosphate injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All donors evaluated as per institutional protocol for donor hepatectomy and found fit&#xD;
&#xD;
          -  Those who consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients refusing to consent for inclusion in the study.&#xD;
&#xD;
          -  Minor hepatectomy&#xD;
&#xD;
          -  Those who develop profound hypophosphatemia in the control group&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viniyendra Pamecha, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Professor and Head, Department of HPB surgery and Liver transplantation, ILBS, New Delhi.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Liver and Biliary Sciences, India</investigator_affiliation>
    <investigator_full_name>Vivek Rajendran</investigator_full_name>
    <investigator_title>Senior Resident, Department of HPB surgery and liver transplantation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Potassium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

